Literature DB >> 19427266

Neurokinin 1 receptor isoforms and the control of innate immunity.

Florin Tuluc1, Jian Ping Lai, Laurie E Kilpatrick, Dwight L Evans, Steven D Douglas.   

Abstract

Substance P is the prototype tachykinin peptide and triggers a variety of biological effects in both the nervous and immune system. Two naturally occurring variants of the neurokinin 1 receptor (NK1R) mediate the effects of SP: a 'classic' full-length receptor and a truncated (tail-less) form that lacks 96 amino acid residues at the C-terminus. Most research has focused on the full length receptor and the truncated NK1R has not been extensively explored. Recent data demonstrate that truncated NK1R has important functional roles, including modulation of responses triggered by cytokines, chemotaxis of macrophages and regulation of HIV replication. Targeting the truncated NK1R with pharmacologic agents might result in novel therapeutic approaches in diseases which affect the immune system, including HIV disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427266     DOI: 10.1016/j.it.2009.03.006

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  50 in total

1.  Detection of the full-length transcript variant for neurokinin-1 receptor in human whole blood associated with enhanced reinforcement of clot by substance-P.

Authors:  Toshiharu Azma; Yuki Sugimoto; Hiroyuki Kinoshita; Taishin Ito; Masanori Tsukamoto; Hiroshi Hoshijima; Masakazu Nakao; Hirosato Kikuchi
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

2.  Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.

Authors:  Mark M Manak; Dmitry A Moshkoff; Lequan T Nguyen; John Meshki; Pablo Tebas; Florin Tuluc; Steven D Douglas
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

Review 3.  Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation.

Authors:  Steven D Douglas; Susan E Leeman
Journal:  Ann N Y Acad Sci       Date:  2010-11-22       Impact factor: 5.691

Review 4.  Alternative splicing of G protein-coupled receptors: physiology and pathophysiology.

Authors:  Danijela Markovic; R A John Challiss
Journal:  Cell Mol Life Sci       Date:  2009-07-23       Impact factor: 9.261

5.  Role of neurokinin-1 receptor in the initiation and maintenance of skin chronic inflammatory diseases.

Authors:  Sherrie J Divito; Adrian E Morelli; Adriana T Larregina
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

6.  Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS.

Authors:  Heather Vinet-Oliphant; Xavier Alvarez; Elizabeth Buza; Juan T Borda; Mahesh Mohan; Pyone P Aye; Florin Tuluc; Steven D Douglas; Andrew A Lackner
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

7.  Tachykinins and Neurokinin Receptors in Bone Marrow Functions: Neural-Hematopoietic Link.

Authors:  Tilman E Klassert; Shyam A Patel; Pranela Rameshwar
Journal:  J Receptor Ligand Channel Res       Date:  2010-04-01

8.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 9.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

10.  Autocrine regulation of human sperm motility by tachykinins.

Authors:  Francisco M Pinto; Cristina G Ravina; Nerea Subiran; Antonio Cejudo-Román; Manuel Fernández-Sánchez; Jon Irazusta; Nicolas Garrido; Luz Candenas
Journal:  Reprod Biol Endocrinol       Date:  2010-08-26       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.